Edgestream Partners L.P. Invests $1.67 Million in Moderna, Inc. (NASDAQ:MRNA)

Edgestream Partners L.P. bought a new position in shares of Moderna, Inc. (NASDAQ:MRNA) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 14,084 shares of the company’s stock, valued at approximately $1,672,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Moderna by 22.6% during the 4th quarter. Vanguard Group Inc. now owns 33,907,072 shares of the company’s stock valued at $3,372,058,000 after acquiring an additional 6,248,623 shares during the period. Wellington Management Group LLP raised its stake in shares of Moderna by 28.8% in the fourth quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock valued at $718,584,000 after acquiring an additional 1,614,460 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in Moderna by 42.9% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,545,829 shares of the company’s stock valued at $164,724,000 after purchasing an additional 463,960 shares during the period. Matrix Capital Management Company LP acquired a new position in Moderna during the 4th quarter worth $45,150,000. Finally, Nikko Asset Management Americas Inc. increased its holdings in Moderna by 156.9% during the 1st quarter. Nikko Asset Management Americas Inc. now owns 741,783 shares of the company’s stock worth $79,044,000 after purchasing an additional 453,004 shares during the period. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Trading Down 2.6 %

Shares of NASDAQ MRNA opened at $68.02 on Friday. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a one year low of $62.55 and a one year high of $170.47. The business has a 50-day moving average price of $91.19 and a two-hundred day moving average price of $110.97. The firm has a market capitalization of $26.07 billion, a PE ratio of -4.34 and a beta of 1.68.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.47) by $0.14. The business had revenue of $241.00 million during the quarter, compared to analyst estimates of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. Moderna’s quarterly revenue was down 29.9% compared to the same quarter last year. During the same period last year, the company earned ($3.62) earnings per share. As a group, analysts predict that Moderna, Inc. will post -9.52 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO James M. Mock sold 689 shares of Moderna stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $118.24, for a total value of $81,467.36. Following the transaction, the chief financial officer now owns 7,269 shares of the company’s stock, valued at $859,486.56. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Moderna news, CFO James M. Mock sold 689 shares of Moderna stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $118.24, for a total value of $81,467.36. Following the transaction, the chief financial officer now directly owns 7,269 shares of the company’s stock, valued at approximately $859,486.56. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $117.08, for a total transaction of $1,756,200.00. Following the transaction, the director now directly owns 2,269,015 shares in the company, valued at approximately $265,656,276.20. The disclosure for this sale can be found here. Insiders sold 93,158 shares of company stock valued at $11,167,312 over the last quarter. Insiders own 15.70% of the company’s stock.

Wall Street Analysts Forecast Growth

MRNA has been the topic of several analyst reports. Barclays reduced their target price on shares of Moderna from $155.00 to $125.00 and set an “overweight” rating on the stock in a report on Monday. Leerink Partners lowered their target price on shares of Moderna from $60.00 to $48.00 and set an “underperform” rating for the company in a research note on Tuesday. Jefferies Financial Group cut Moderna from a “buy” rating to a “hold” rating and cut their price target for the company from $120.00 to $65.00 in a research note on Friday, September 13th. Royal Bank of Canada restated a “sector perform” rating and set a $75.00 target price on shares of Moderna in a research note on Thursday. Finally, Evercore ISI reiterated an “in-line” rating and issued a $120.00 price target on shares of Moderna in a research note on Thursday, June 27th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $100.44.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.